PL2539366T3 - Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach - Google Patents
Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiachInfo
- Publication number
- PL2539366T3 PL2539366T3 PL11713058T PL11713058T PL2539366T3 PL 2539366 T3 PL2539366 T3 PL 2539366T3 PL 11713058 T PL11713058 T PL 11713058T PL 11713058 T PL11713058 T PL 11713058T PL 2539366 T3 PL2539366 T3 PL 2539366T3
- Authority
- PL
- Poland
- Prior art keywords
- protofibril
- synucleinopathies
- dementia
- parkinson
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30863810P | 2010-02-26 | 2010-02-26 | |
| US40626010P | 2010-10-25 | 2010-10-25 | |
| PCT/IB2011/050826 WO2011104696A1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| EP11713058.3A EP2539366B1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2539366T3 true PL2539366T3 (pl) | 2018-06-29 |
Family
ID=44227520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11713058T PL2539366T3 (pl) | 2010-02-26 | 2011-02-25 | Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8632776B2 (pl) |
| EP (1) | EP2539366B1 (pl) |
| JP (1) | JP5894939B2 (pl) |
| CN (3) | CN110655573B (pl) |
| AU (1) | AU2011219414B2 (pl) |
| CA (1) | CA2789963C (pl) |
| CY (1) | CY1120014T1 (pl) |
| DK (1) | DK2539366T3 (pl) |
| ES (1) | ES2661925T3 (pl) |
| HR (1) | HRP20180230T8 (pl) |
| HU (1) | HUE038313T2 (pl) |
| LT (1) | LT2539366T (pl) |
| NO (1) | NO2539366T3 (pl) |
| PL (1) | PL2539366T3 (pl) |
| PT (1) | PT2539366T (pl) |
| RS (1) | RS57029B1 (pl) |
| RU (1) | RU2555526C2 (pl) |
| SI (1) | SI2539366T1 (pl) |
| SM (1) | SMT201800044T1 (pl) |
| WO (1) | WO2011104696A1 (pl) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| CN110655573B (zh) | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| US10989718B2 (en) * | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| BR112014017814A8 (pt) * | 2012-01-20 | 2017-07-11 | Genzyme Corp | Anticorpos anti-cxcr3 |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| LT3071597T (lt) | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| CN106661103B (zh) * | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| US10494425B2 (en) * | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| EP3325506A1 (en) | 2015-07-21 | 2018-05-30 | BioArctic AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| KR102964291B1 (ko) | 2015-11-09 | 2026-05-13 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
| US10774120B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| CA3004482A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
| TW202309093A (zh) * | 2016-06-02 | 2023-03-01 | 英商梅迪繆思有限公司 | 針對α-突觸核蛋白之抗體及其用途 |
| CA3028035A1 (en) | 2016-07-14 | 2018-01-18 | Bioarctic Ab | Brain delivery protein |
| KR102550991B1 (ko) | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| WO2018128454A1 (ko) * | 2017-01-06 | 2018-07-12 | 에이비엘바이오 주식회사 | 항 α-SYN 항체 및 그 용도 |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| AU2018255489B2 (en) * | 2017-04-21 | 2024-06-13 | Implicit Bioscience Limited | CD 14 antagonist antibodies for treating neurodegenerative diseases |
| IL270361B2 (en) * | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| KR20200007945A (ko) | 2017-05-16 | 2020-01-22 | 암프리온, 인코퍼레이티드 | 미스폴딩된 타우 단백질의 검출 |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| EP3672635A4 (en) * | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF |
| RU2657763C1 (ru) * | 2017-09-12 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики болезни паркинсона |
| BR112020009707A2 (pt) * | 2017-11-17 | 2020-10-13 | Abl Bio Inc. | anticorpos para a-sinucleína e usos dos mesmos |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| EP3728567B1 (en) | 2017-12-19 | 2023-07-05 | Chase Therapeutics Corporation | Method for assessing a synucleinopathy |
| JP7498663B2 (ja) * | 2017-12-21 | 2024-06-12 | ハー・ルンドベック・アクチエゼルスカベット | アルファ－シヌクレイン病のアッセイ、方法、及び治療 |
| CN109957547A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957546A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| US12583894B2 (en) | 2018-04-04 | 2026-03-24 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of Lewy body disorders |
| TW202003576A (zh) * | 2018-05-10 | 2020-01-16 | 美商艾博視訊有限公司 | 活化cd40之單株抗體及其用途 |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| WO2020023530A2 (en) | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
| TW202039562A (zh) * | 2018-12-12 | 2020-11-01 | 大陸商上海藥明生物技術有限公司 | 抗tim-3抗體及其用途 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| WO2020192754A1 (en) * | 2019-03-28 | 2020-10-01 | The Chinese University Of Hong Kong | Sumo peptides for treating neurodegenerative diseases |
| US20220214360A1 (en) | 2019-04-30 | 2022-07-07 | Chase Therapeutics Corporation | Alpha-synuclein assays |
| US20220291240A1 (en) * | 2019-08-27 | 2022-09-15 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| PH12022551608A1 (en) | 2019-12-31 | 2023-10-16 | Chase Therapeutics Corp | Kinases as biomarkers for neurodegenerative conditions |
| CN111171152B (zh) * | 2020-01-15 | 2023-04-18 | 吉林医药学院 | Pcsk9抗体及其制备方法和应用 |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| HRP20250812T1 (hr) * | 2020-06-26 | 2025-09-12 | Bioarctic Ab | Antitijela koja vežu alfa-sinuklein protofibril |
| US20230365665A1 (en) | 2020-09-17 | 2023-11-16 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES |
| KR20230157296A (ko) * | 2020-12-16 | 2023-11-16 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| JP2024525559A (ja) | 2021-07-09 | 2024-07-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病治療用バイオマーカー |
| CA3230148A1 (en) | 2021-08-30 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| KR20240142535A (ko) | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
| JP2023132247A (ja) * | 2022-03-10 | 2023-09-22 | 公立大学法人大阪 | シヌクレイノパシー検出用バイオマーカー及びその利用 |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
| CN119101159A (zh) * | 2024-08-30 | 2024-12-10 | 山东大学 | 抗tim-3单克隆抗体及其制备方法和应用 |
| WO2026068513A1 (en) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000002053A2 (en) | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20060018918A1 (en) | 2000-12-27 | 2006-01-26 | Board Of Regents, The University Of Texas System | Production of stabilized conformational isomers of disease associated proteins |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| UA93653C2 (ru) * | 2003-11-07 | 2011-03-10 | Иммунекс Корпорейшн | Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r) |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| JP2009525046A (ja) | 2006-01-31 | 2009-07-09 | エラン ファーマシューティカルズ，インコーポレイテッド | アルファ−シヌクレインキナーゼ |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
| ES2709048T3 (es) * | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| SI2448968T1 (sl) | 2009-06-29 | 2021-07-30 | Bioarctic Ab | Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta |
| CN110655573B (zh) | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
-
2011
- 2011-02-25 CN CN201910950804.0A patent/CN110655573B/zh active Active
- 2011-02-25 AU AU2011219414A patent/AU2011219414B2/en active Active
- 2011-02-25 CN CN201180011363.XA patent/CN102869680B/zh active Active
- 2011-02-25 DK DK11713058.3T patent/DK2539366T3/en active
- 2011-02-25 HR HRP20180230TT patent/HRP20180230T8/hr unknown
- 2011-02-25 ES ES11713058.3T patent/ES2661925T3/es active Active
- 2011-02-25 NO NO11713058A patent/NO2539366T3/no unknown
- 2011-02-25 LT LTEP11713058.3T patent/LT2539366T/lt unknown
- 2011-02-25 CA CA2789963A patent/CA2789963C/en active Active
- 2011-02-25 SI SI201131419T patent/SI2539366T1/en unknown
- 2011-02-25 EP EP11713058.3A patent/EP2539366B1/en active Active
- 2011-02-25 PT PT117130583T patent/PT2539366T/pt unknown
- 2011-02-25 US US13/578,710 patent/US8632776B2/en active Active
- 2011-02-25 RU RU2012140954/10A patent/RU2555526C2/ru active
- 2011-02-25 HU HUE11713058A patent/HUE038313T2/hu unknown
- 2011-02-25 WO PCT/IB2011/050826 patent/WO2011104696A1/en not_active Ceased
- 2011-02-25 CN CN201610801424.7A patent/CN106397588B/zh active Active
- 2011-02-25 RS RS20180129A patent/RS57029B1/sr unknown
- 2011-02-25 JP JP2012554464A patent/JP5894939B2/ja active Active
- 2011-02-25 SM SM20180044T patent/SMT201800044T1/it unknown
- 2011-02-25 PL PL11713058T patent/PL2539366T3/pl unknown
-
2013
- 2013-08-01 US US13/957,239 patent/US8859501B2/en active Active
-
2014
- 2014-08-28 US US14/472,036 patent/US8968734B2/en active Active
-
2015
- 2015-02-02 US US14/611,690 patent/US9084832B2/en active Active
-
2018
- 2018-02-05 CY CY20181100140T patent/CY1120014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2539366T (pt) | Anticorpos de ligação a protofibrilas e sua utilização em métodos terapêuticos e diagnósticos para a doença de parkinson, demência com corpos de lewy e outras alfa-sinucleinopatias | |
| HUE041223T2 (hu) | Antitestek és vakcinák alfa-szinukleinnel összefüggõ betegségek terápiás és diagnosztikai eljárásaiban történõ alkalmazásra | |
| IL243537A0 (en) | Artificial triterpenoids and methods for use in the treatment of disease | |
| PT3042910T (pt) | 2'-espiro-nucleósidos para utilização na terapia da hepatite c | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| AP2014007601A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| GB201105137D0 (en) | Therapeutic molecules for use in the suppression of Parkinson's disease | |
| LT2739615T (lt) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanonai ir jų panaudojimas kaip vaisto | |
| IL217293A0 (en) | NOVEL 1,2,3,4 - TETRAHYDROPYRIMIDO {1,2-a} PYRIMIDIN - 6 - ONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | |
| GB0918392D0 (en) | Diagnostic and therapeutic methods | |
| IL217209A0 (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| EP2670769A1 (en) | R2r1/2 in diagnosis and therapy | |
| PL2453217T3 (pl) | Bezspoinowy korpus wagi oraz metoda jego produkcji | |
| EP2348865A4 (en) | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| PL2593129T3 (pl) | Nonapeptyd pat do stosowania w leczeniu choroby alzheimera | |
| HK1170538A (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| Hume | Roger L’Estrange and the Making of Restoration Culture. | |
| AU2011900573A0 (en) | Alzheimer's Disease Biomarkers and Methods Using the Same | |
| HK1196617A (en) | Novel purine derivatives and their use in the treatment of disease | |
| GB0703450D0 (en) | Tropane derivatives, processes for their preparation and their use in medicine | |
| PL387749A1 (pl) | Nowe pochodne 4,5,6,7-tetrajodobenzimidazolu, sposób ich otrzymywania i zastosowanie medyczne |